Study of CT1190B for relapsed or refractory B-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests an experimental drug called CT1190B for people with a type of blood cancer (B-cell non-Hodgkin lymphoma) that has come back or stopped responding to at least two prior treatments. The study aims to see if the drug can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You have a confirmed diagnosis of B-cell non-Hodgkin lymphoma
- You have tried at least 2 standard treatments and your cancer got worse or you can't tolerate those treatments
- You have at least one measurable tumor on scans
- You are generally well enough to be up and about (ECOG score 0-1)
- You agree to use effective birth control for 1 year after treatment, if applicable
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new cell therapy called CT1190B for people with certain types of B-cell lymphoma that came back or did not improve after other treatments. The therapy uses your own immune cells to fight the cancer, and the study aims to see if it is safe and effective.
This trial tests a new treatment called CT1190B for people with B-cell non-Hodgkin lymphoma that has come back or stopped responding to at least two prior therapies. It aims to see if CT1190B can help when other treatments have failed or caused side effects.
This study tests a new cancer treatment called CT1190B for people with certain types of B-cell lymphoma that have not responded to or came back after other treatments. The goal is to see if it can help shrink or control the lymphoma.
This trial tests a new treatment called CT1194C for patients with B-cell non-Hodgkin lymphoma that has returned or not responded to at least two previous treatments. It aims to see if this treatment can help control the lymphoma and is safe.
This study tests a new treatment called CT1190B for people with large B-cell lymphoma that has come back or hasn't responded to at least two prior treatments. The goal is to see if this treatment can help shrink or control the cancer.
This trial tests a new type of CAR-T cell therapy designed to be stronger against B-cell lymphoma that has come back or not responded to previous treatments. The treatment uses your own immune cells, which are modified in a lab to better attack cancer cells.
Hear when a new B-Cell Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.